UCA and Curaxys create a Cathedra in biopharmaceutical to research biosimilar proteins

jul/6th/2010 | OTRIcompartir noticiaimprimir

Para compartir esta información, incluye en el siguiente formulario tu nombre y un correo electrónico de destino.

The Chair Curaxys will dedicate their practice in biological drug development, and training of researchers and managers in biotechnology

The production of this kind of biogenerics poses a major challenge to both the company and the university

The University of Cadiz and the biopharmaceutical company Curaxys presented this morning the new Cathedra Curaxys, which aims to promote and facilitate the research in biotechnology led to the production of therapeutic biosimilar proteins, with views to its clinical application, in addition, researchers will be trained, as well as, technologists and professionals of health sciences in the clinical application of biotechnological knowledge.

The Dean of the University of Cádiz, Diego Sales, and Curaxys CEO, Manuel Esteban, this morning signed a collaboration agreement in the collegiate building la Bomba, where the Director of the Cathedra Curaxys, Carmen Castro, has made the public presentation. Sales highlighted the relevance of this project in the society of Cadiz, being led by a prestigious Gaditan scientist and also because she has succeeded in uniting in the Cathedra "the knowledge of several research groups in biomedicine as a tool for social services, through training, research and transfer of results.”

Esteban reminded Curaxys will develop in El Puerto de Santa Maria a biopharmaceutical centre and a plant, which will produce injections. A relevant project, whose main feature is the added value given to the natural products the researchers will work with, such as oil or sugar, which will be used for bio-similar medication. The spokesman of Curaxys said the Cathedra will integrate "all the positive values of the University and Curaxys, with the support of the agency IDEA and the Foundation for Biomedicine."

The Director of the Chair, Professor Carmen Castro said that "the therapeutic proteins are drugs that are biological in nature and have been used in recent years for the treatment of diseases such as diabetes, cancer, lupus or cystic fibrosis." In this category, there are substances such as insulin, which is well-known for its important role in the treatment of diabetes, interferon, which is used to treat some types of cancer, or rituximab for the treatment of lupus or erythropoietin, also known as EPO, is also being used for the treatment of anemia of renal origin. "

Similarly, Castro recalled that "these drugs are very expensive and are sometimes the only existing treatment for diseases of this kind." The causes of the high cost of these substances are due to the complex production process. However, the solution could arrive soon, "because the patents on these drugs are beginning to wither away, issue that favours the start-up of producing bio-similar proteins with a more innovative and competitive biological process."

On the contrary of the chemical nature of the drugs, the production of biological substances is costly and not easy to carry-out, having to occur within a living organism, so it requires complicated tools of biotechnology. Thus the production of this kind of biogenerics poses a major challenge to both the company and the university.

In terms of training, it has been accorded to establish an investigative pre-doctoral scholarship, which will persist four years, for the attainment of a doctoral thesis in the field of biotechnology applied to therapeutic proteins. We also intend to create a Masters in Biotechnology, but "before we had proposed the creation of an Expert degree in Biotechnology, clearly directed to the area of business." While these goals are being fulfilled, "in a short term period, we will focus on collaborating with the Master program in Biomedicine", said Professor Carmen Castro.

The Cathedra of Curaxys initiated its innovative activity with a team of researchers from the company Curaxys SL and a Scientific Committee constituted by members of the Department of Biomedicine, Biotechnology and Public Health of the UCA, an area addressed by Professor Jesús Manuel Cantoral.

Therapeutical proteins of biological origin

The technology-based company Curaxys S.L. specializes in the production of therapeutic proteins, which is of great interest to the public health. The processes of Biological molecular are highly competitive and are based on the development of expression systems, the cultivation of industrial cell, extraction and purification of proteins. To carry out these activities, Curaxys SL plans to invest 40 million euros in building a technological centre and a biopharmaceutical and injection production plant.

The company is located in TecnoBahía, who hopes to enjoy the new facilities during the second half of 2012 and create 90 direct jobs and 270 indirect jobs. This business initiative is supported by the Action Plan Competitive Bay (Agency IDEA, Andalusian Government) and the Plan of Reindustrialisation of the Bay of Cadiz, sponsored by the Ministry of Industry, Tourism and Trade.

*Recombinant proteins, monoclonal antibodies or nucleic acids equivalent to an original treatment that can be manufactured after the expiration of the patents. Drug patents extinguished, which come from non-chemical proteins, such as insulin, the hormone EPO and growth hormone, among others.

tags» investigation biofarmacia chair curaxys

más contenidos


contact | newsletter | legal noticy | privacy | accessibility (wai) | validation XHTML/CSS | intranet

Unidad de Cultura Científica y de la Innovación (UCC+i) | Vicerrectorado de Investigación

Edificio Hospital Real | Plaza Falla, 8 - 11003, Cádiz | Teléfono (+34) 956 015 745 - 956 016 590 | mail culturacientifica@uca.es